Despite significant advances in the frontline treatment of chronic lymphocytic leukemia (CLL), patients eventually experience disease progression. Treatment selection of relapsed disease depends upon a variety of factors, including patient age, performance status, duration of response to initial therapy, type of prior therapy, disease-related manifestations and genetic abnormalities within the CLL cells. This presentation offers synthetic overview of the options in this field.

中文翻译：

---

慢性淋巴细胞白血病：复发的治疗

尽管慢性淋巴细胞白血病 (CLL) 的一线治疗取得了重大进展，但患者最终会经历疾病进展。复发疾病的治疗选择取决于多种因素，包括患者年龄、体能状态、对初始治疗的反应持续时间、先前治疗的类型、疾病相关表现和 CLL 细胞内的遗传异常。本演示文稿提供了该领域选项的综合概述。